About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

106.54 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 106.54
Bid (Size) 105.77 (1)
Ask (Size) 105.81 (8)
Prev. Close 106.54
Today's Range 106.54 - 106.54
52wk Range 92.19 - 108.78
Shares Outstanding N/A
Dividend Yield 3.26%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Superlab Suisse opens state-of-the-art facility in Basel, fostering new spaces for scientific breakthroughs
With this new facility, Superlab Suisse becomes the largest private lab space in Switzerland. 
Via News Direct
Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade
Novartis stock is in a buy range after moving past a 103.55 entry in a cup with handle. The buy range extends to 5% above the initial entry. 
Via Investor's Business Daily

Performance

YTD
+5.49%
+5.49%
1 Month
+3.68%
+3.68%
3 Month
+11.13%
+11.13%
6 Month
+5.49%
+5.49%
1 Year
+7.87%
+7.87%

More News

Read More
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line
Via Benzinga
Exploring NYSE:NVS's dividend characteristics.
Via Chartmill
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Via Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
Via Chartmill
What's Going On With Neurological Disease Focused Trevena On Thursday?
Via Benzinga
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
3 Crazy Good Stocks to Buy With $500 Right Now
Via InvestorPlace
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Via Benzinga
Leigh Burgess, CEO & Founder Bold Industries Group, Announces Pre-Sale of New Book: Be BOLD Today
Via Get News
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024
Via InvestorPlace
Novartis Sues to Block Maryland's New Drug Discount Law
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety
Via Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
Via Benzinga
Topics Data Breach
Exposures Information Security
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Via Benzinga
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
3 Magnificent Stocks That Are Passive Income Machines
Via The Motley Fool
The 3 Best Mutual Funds to Buy in May 2024
Via InvestorPlace
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Via Benzinga
3 Biotech Stocks to Sell in May Before They Crash & Burn
Via InvestorPlace
Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Axmed raises $2 million to transform access to critical medicines in low and middle income countries
Via News Direct
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.